BioSpace News Archive

LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. announced that it has discontinued development of fezagepras.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma’s novel drug candidate, olverembatinib (HQP1351).

InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Gritstone bio, Inc. announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results, and provide a corporate update.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022.

Marvel Biosciences Inc. (TSXV: MRVL) (the “Company” or “Marvel”) is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.

The West Coast Consortium for Technology & Innovation in Pediatrics, centered at Children’s Hospital Los Angeles, presented its 2022 Symposium entitled “Patient Impact, Patient Voice,” bringing innovators, clinicians and patient families together virtually to discuss the importance of better integrating patients and their perspectives into the design, development and research of pediatric medical devices.